Alert icon

To align with industry best practices for security and data integrity, Project Data Sphere is requiring users to upgrade their browsers to one that supports encryption protocol TLS 1.2 by December 15, 2017. On that date, Project Data Sphere will disable support of browsers that permit SSL 3.0/TLS 1.0. To prevent any disruption to your access to Project Data Sphere, you must take action.
This browser was not recognized and may not be compatible with TLS 1.2 or higher. Please check with the browser's developer to confirm.
To view information about this, please visit the FAQ. If you have any further questions, please contact us.

Back to the List
Type(s) of Cancer
Uterine
Study Phase
Phase 3
Study Completion Date
2012
NCT01533207Uploaded 02-12-2020
Access via NCI by Request
PDS UID: nci-data-405
N/A
Provider Information
Provider Data DescriptionThis dataset will allow users to reproduce the treatment comparison between Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin and Observation from PubMed 30289732.
SponsorGynecologic Oncology Group
Data ProviderNational Cancer Institute
Clinical Trials.gov Information
Brief SummaryN/A
ConditionsN/A
Intervention TypeDrug, Biologics, Other
Drug(s)N/A
Total EnrolledN/A
RandomizationN/A
Blinding MethodN/A
Arms InterventionN/A
Secondary IDN/A
PubMed (PMID)N/A
Collaborator(s)N/A
Region(s)N/A
Age RangeN/A
Files: NCT01533207-D1
Data DictionaryNCT01533207-D1-Data-Dictionary_1.pdf
DATANCT01533207-D1-Dataset_1.csv
OTHERREADME.pdf
Files: NCT01533207-D2
Data DictionaryNCT01533207-D2-Data-Dictionary_2.pdf
DATANCT01533207-D2-Dataset_1.csv
OTHERREADME.pdf
© 2023 Project Data Sphere
All rights reserved
Privacy PolicyTerms of Use